A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer
AP32788 is an investigational drug designed to inhibit the growth of cancers with a mutated version of the EGFR and HER2 proteins. In this study, researchers are evaluating the safety and effectiveness of AP32788 in patients with advanced or metastatic non-small cell lung cancer (NSCLC). AP32788 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have stage IIIB or IV NSCLC that cannot be successfully treated with standard therapies.
- At least 2 weeks must pass between the completion of prior therapies (4 weeks since any major surgery) and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Gregory Riely at 646-888-4199.